Natera, Inc. (NTRA)
391.11
-13.68
(-3.38%)
USD |
NASDAQ |
Oct 16, 13:09
Natera SG&A Expense (TTM) : 1.255B for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.255B |
| March 31, 2026 | 1.238B |
| December 31, 2025 | 1.177B |
| September 30, 2025 | 1.121B |
| June 30, 2025 | 1.026B |
| March 31, 2025 | 913.90M |
| December 31, 2024 | 841.31M |
| September 30, 2024 | 767.83M |
| June 30, 2024 | 708.42M |
| March 31, 2024 | 662.96M |
| December 31, 2023 | 618.31M |
| September 30, 2023 | 600.70M |
| June 30, 2023 | 593.62M |
| March 31, 2023 | 590.58M |
| December 31, 2022 | 588.59M |
| September 30, 2022 | 591.53M |
| June 30, 2022 | 572.35M |
| March 31, 2022 | 550.34M |
| December 31, 2021 | 511.03M |
| September 30, 2021 | 458.35M |
| June 30, 2021 | 405.55M |
| March 31, 2021 | 346.28M |
| December 31, 2020 | 303.63M |
| September 30, 2020 | 268.13M |
| June 30, 2020 | 249.17M |
| Date | Value |
|---|---|
| March 31, 2020 | 228.02M |
| December 31, 2019 | 206.18M |
| September 30, 2019 | 188.72M |
| June 30, 2019 | 170.38M |
| March 31, 2019 | 160.78M |
| December 31, 2018 | 154.87M |
| September 30, 2018 | 162.68M |
| June 30, 2018 | 158.78M |
| March 31, 2018 | 155.65M |
| December 31, 2017 | 155.31M |
| September 30, 2017 | 143.92M |
| June 30, 2017 | 144.38M |
| March 31, 2017 | 143.30M |
| December 31, 2016 | 136.13M |
| September 30, 2016 | 129.02M |
| June 30, 2016 | 121.95M |
| March 31, 2016 | 116.81M |
| December 31, 2015 | 109.64M |
| September 30, 2015 | 95.50M |
| June 30, 2015 | 81.53M |
| March 31, 2015 | 67.83M |
| September 30, 2014 | 44.59M |
| June 30, 2014 | 28.28M |
| March 31, 2014 | 14.38M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Guardant Health, Inc. | 863.63M |
| Myriad Genetics, Inc. | 539.90M |
| CareDx, Inc. | 247.69M |
| Caris Life Sciences, Inc. | 418.96M |
| BioRestorative Therapies, Inc. | 5.181M |